 |
27 Products |  |
14 Diseases | | 27 Products |
|
40 Trials |  |
6145 News |  |
| «12...56575859606162636465666768 |
- birinapant (IGM-9427) / IGM Biosciences
Trial withdrawal: 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant (clinicaltrials.gov) - Jul 24, 2013
P2, N=0, Withdrawn, Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting --> Withdrawn
- birinapant (IGM-9427) / IGM Biosciences
Enrollment change: 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant (clinicaltrials.gov) - Jul 24, 2013
P2, N=0, Withdrawn, Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting --> Withdrawn N=10 --> 0
- | INXN-3001 / Precigen, Alaunos Therap
Trial completion: Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma (clinicaltrials.gov) - Jul 16, 2013
P1, N=12, Completed, Sponsor: Ziopharm
N=10 --> 0 Active, not recruiting --> Completed
- birinapant (IGM-9427) / IGM Biosciences
Enrollment change: Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma (clinicaltrials.gov) - May 20, 2013
P1, N=50, Completed, Sponsor: TetraLogic Pharmaceuticals
Active, not recruiting --> Completed N=65 --> 50
- | birinapant (IGM-9427) / IGM Biosciences
Trial completion: Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma (clinicaltrials.gov) - May 20, 2013
P1, N=50, Completed, Sponsor: TetraLogic Pharmaceuticals
N=65 --> 50 Active, not recruiting --> Completed
- | birinapant (IGM-9427) / IGM Biosciences
New P1/2 trial, Combination therapy: Birinapant With 5-azacitidine in MDS Subjects Who Are Na (clinicaltrials.gov) - Apr 8, 2013
P1/2, N=45, Recruiting, Sponsor: TetraLogic Pharmaceuticals
- |||| Ad-RTS-hIL-12 / Alaunos Therap, Zymafos (palifosfamide) / Alaunos Therap
Enrollment open, Monotherapy, Metastases, Viral vector: Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer. (clinicaltrials.gov) - Mar 20, 2013
P2, N=68, Recruiting, Sponsor: Ziopharm
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- MazF gene therapy / Takara
New P1 trial, Gene therapy, Viral vector: Redirected MazF-CD4 Autologous T Cells for HIV Gene Therapy (clinicaltrials.gov) - Feb 7, 2013
P1, N=12, Recruiting, Sponsor: University of Pennsylvania
- ||| Ad-RTS-hIL-12 / Alaunos Therap, Zymafos (palifosfamide) / Alaunos Therap
Trial initiation date, Monotherapy, Metastases, Viral vector: Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer. (clinicaltrials.gov) - Jan 10, 2013
P2, N=68, Recruiting, Sponsor: Ziopharm
Not yet recruiting --> Recruiting Initiation date: Nov 2012 --> Mar 2013
- birinapant (IGM-9427) / IGM Biosciences
New P2 trial: 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant (clinicaltrials.gov) - Jan 9, 2013
P2, N=0, Withdrawn, Sponsor: National Institutes of Health Clinical Center (CC)
- Kymriah (tisagenlecleucel-T) / Novartis
Enrollment change: CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy (clinicaltrials.gov) - Dec 18, 2012
P=N/A, N=14, Completed, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Initiation date: Nov 2012 --> Mar 2013 N=10 --> 14
- Kymriah (tisagenlecleucel-T) / Novartis
New P2 trial: Dose Optimization Trial of CD19 Redirected Autologous T Cells (clinicaltrials.gov) - Dec 9, 2012
P2, N=32, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
- | Ad-RTS-hIL-12 / Alaunos Therap
Enrollment change, Combination therapy: Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma (clinicaltrials.gov) - Oct 21, 2012
P1/2, N=30, Recruiting, Sponsor: Ziopharm
N=10 --> 14 N=18 --> 30
- Kymriah (tisagenlecleucel-T) / Novartis
Enrollment closed: Allo CART-19 Protocol (clinicaltrials.gov) - Oct 10, 2012
P1, N=10, Active, not recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
N=18 --> 30 Recruiting --> Active, not recruiting
- ||||| Ad-RTS-hIL-12 / Alaunos Therap, Zymafos (palifosfamide) / Alaunos Therap
New P2 trial, Monotherapy, Metastases, Viral vector: Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer. (clinicaltrials.gov) - Oct 8, 2012
P2, N=68, Recruiting, Sponsor: Ziopharm
- ||| birinapant (IGM-9427) / IGM Biosciences
Enrollment closed, Combination therapy, Metastases: Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Sep 26, 2012
P1b/2a, N=200, Active, not recruiting, Sponsor: TetraLogic Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- birinapant (IGM-9427) / IGM Biosciences
New P2 trial: Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer (clinicaltrials.gov) - Sep 5, 2012
P2, N=11, Completed, Sponsor: National Cancer Institute (NCI)
- Kymriah (tisagenlecleucel-T) / Novartis
New P1 trial: Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma (clinicaltrials.gov) - Jun 20, 2012
P1, N=20, Recruiting, Sponsor: Children's Hospital of Philadelphia
- birinapant (IGM-9427) / IGM Biosciences
New P1 trial: Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 8, 2012
P1, N=21, Terminated, Sponsor: Roswell Park Cancer Institute
- Kymriah (tisagenlecleucel-T) / Novartis
New P1 trial: Allo CART-19 Protocol (clinicaltrials.gov) - Mar 8, 2012
P1, N=10, Active, not recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
- birinapant (IGM-9427) / IGM Biosciences
New P1/2 trial: A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 5, 2011
P1/2, N=37, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
- ||| birinapant (IGM-9427) / IGM Biosciences
Enrollment change, Combination therapy, Metastases: Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Sep 11, 2011
P1b/2a, N=200, Active, not recruiting, Sponsor: TetraLogic Pharmaceuticals
Recruiting --> Active, not recruiting N=120 --> 200
- | Ad-RTS-hIL-12 / Alaunos Therap
Enrollment open, Combination therapy: Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma (clinicaltrials.gov) - Aug 22, 2011
P1/2, N=30, Recruiting, Sponsor: Ziopharm
N=120 --> 200 Active, not recruiting --> Recruiting